About: COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature
Creator	Pazgan-Simon, Monika Kotfis, Katarzyna Lara, Luis Marlicz, Wojciech Koulaouzidis, Anastasios Skonieczna-Żydecka, Karolina Maciejewska, Dominika Stachowska, Ewa Kaczmarczyk, Mariusz Kukla, Michał
source	Medline; PMC
abstract	The novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection has been predominantly linked to respiratory distress syndrome, but gastrointestinal symptoms and hepatic injury have also been reported. The mechanism of liver injury is poorly understood and may result as a consequence of viral hepatitis, systemic inflammatory response, gut barrier and microbiome alterations, intensive care treatment or drug toxicity. The incidence of hepatopathy among patients with coronavirus disease 2019 (COVID-19) is unclear, but studies have reported liver injury in patients with SARS and Middle East respiratory syndrome (MERS). We aimed to systematically review data on the prevalence of hepatic impairments and their clinical course in SARS and MERS Coronaviridae infections. A systematic literature search (PubMed/Embase/Cinahl/Web of Science) according to preferred reporting items for systematic review and meta-analysis protocols (PRISMA) was conducted from database inception until 17/03/2020 for studies that evaluated the incidence of hepatic abnormalities in SARS CoV-1, SARS CoV-2 and MERS infected patients with reported liver-related parameters. A total of forty-three studies were included. Liver anomalies were predominantly mild to moderately elevated transaminases, hypoalbuminemia and prolongation of prothrombin time. Histopathology varied between non-specific inflammation, mild steatosis, congestion and massive necrosis. More studies to elucidate the mechanism and importance of liver injury on the clinical course and prognosis in patients with novel SARS-CoV-2 infection are warranted.
has issue date	2020-05-11(xsd:dateTime)
bibo:doi	10.3390/jcm9051420
bibo:pmid	32403255
has license	cc-by
sha1sum (hex)	ac93be2a751f83a13050a800063cbfb2b5d74d92
schema:url	https://doi.org/10.3390/jcm9051420
resource representing a document's title	COVID-19, MERS and SARS with Concomitant Liver Injury—Systematic Review of the Existing Literature
has PubMed Central identifier	PMC7290752
has PubMed identifier	32403255
schema:publication	J Clin Med
resource representing a document's body	covid:ac93be2a751f83a13050a800063cbfb2b5d74d92#body_text
is schema:about of	named entity 'CONSEQUENCE OF' named entity 'INCIDENCE' named entity 'IMPAIRMENTS' named entity 'INCLUDED' named entity 'SARS-COV-2 INFECTION' named entity 'NOVEL CORONAVIRUS' named entity 'coronavirus' named entity 'hypoalbuminemia' named entity 'liver' named entity 'Middle East respiratory syndrome' named entity 'Embase' named entity 'SARS-CoV-2' named entity 'MERS' named entity 'SARS' named entity 'Clinical Medicine' named entity 'MERS' named entity 'viral hepatitis' named entity 'SARS-CoV-2' named entity 'systemic inflammatory response syndrome' named entity 'SARS-CoV-2' named entity 'urea' named entity 'serum creatinine' named entity 'cirrhosis' named entity 'small intestine' named entity 'MERS' named entity 'receptor' named entity 'CVD' named entity 'LDH' named entity 'cell types' named entity 'liver' named entity 'SARS' named entity 'respiratory failure' named entity 'µmol/L' named entity 'adrenal gland' named entity 'COPD' named entity 'OBservational Studies' named entity 'ICU' named entity 'COVID-19' named entity 'clinical practice guidelines' named entity 'liver injury' named entity 'chronic liver disease' named entity 'type 2 diabetes mellitus' named entity 'pneumonia' named entity 'lymphocyte count' named entity 'COVID' named entity 'COVID-19' named entity 'fibrinogen' named entity 'infection' named entity 'ECMO' named entity 'Web of Science' named entity 'SARS' named entity 'COVID-19' named entity 'ACE2' named entity 'prothrombin time' named entity 'chronic liver disease' named entity 'infection' named entity 'liver injury' named entity 'lungs' named entity 'glucose' named entity 'organ' named entity 'Liver' named entity 'BMI' named entity 'respiratory distress syndrome' named entity 'NAFLD' named entity 'coronaviruses' named entity 'histopathology' named entity 'immune response' named entity 'infection' named entity 'viral replication' named entity 'SARS' named entity 'non-specific' named entity 'prothrombin time'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software